PL3204386T3 - Podstawione związki aminopurynowe, ich kompozycje i sposoby leczenia nimi - Google Patents
Podstawione związki aminopurynowe, ich kompozycje i sposoby leczenia nimiInfo
- Publication number
- PL3204386T3 PL3204386T3 PL15848476T PL15848476T PL3204386T3 PL 3204386 T3 PL3204386 T3 PL 3204386T3 PL 15848476 T PL15848476 T PL 15848476T PL 15848476 T PL15848476 T PL 15848476T PL 3204386 T3 PL3204386 T3 PL 3204386T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- methods
- aminopurine compounds
- treatment therewith
- substituted aminopurine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060339P | 2014-10-06 | 2014-10-06 | |
| EP15848476.6A EP3204386B1 (en) | 2014-10-06 | 2015-10-05 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| PCT/US2015/053941 WO2016057370A1 (en) | 2014-10-06 | 2015-10-05 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3204386T3 true PL3204386T3 (pl) | 2021-09-20 |
Family
ID=55632334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15848476T PL3204386T3 (pl) | 2014-10-06 | 2015-10-05 | Podstawione związki aminopurynowe, ich kompozycje i sposoby leczenia nimi |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US9512124B2 (enExample) |
| EP (2) | EP3204386B1 (enExample) |
| JP (4) | JP6884701B2 (enExample) |
| KR (2) | KR102504849B1 (enExample) |
| CN (2) | CN113248506A (enExample) |
| AR (2) | AR102171A1 (enExample) |
| AU (2) | AU2015328414B2 (enExample) |
| CA (1) | CA2963639C (enExample) |
| CL (1) | CL2017000820A1 (enExample) |
| CO (1) | CO2017003838A2 (enExample) |
| CY (1) | CY1124173T1 (enExample) |
| DK (1) | DK3204386T3 (enExample) |
| EA (1) | EA201790779A1 (enExample) |
| EC (1) | ECSP17026210A (enExample) |
| ES (2) | ES2871142T3 (enExample) |
| HR (1) | HRP20210656T1 (enExample) |
| HU (1) | HUE054694T2 (enExample) |
| IL (2) | IL251566B (enExample) |
| LT (1) | LT3204386T (enExample) |
| MX (2) | MX388321B (enExample) |
| PL (1) | PL3204386T3 (enExample) |
| PT (1) | PT3204386T (enExample) |
| RS (1) | RS61884B1 (enExample) |
| SG (2) | SG10202009598VA (enExample) |
| SI (1) | SI3204386T1 (enExample) |
| SM (1) | SMT202100302T1 (enExample) |
| TW (1) | TW201629063A (enExample) |
| WO (1) | WO2016057370A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3204386T (lt) * | 2014-10-06 | 2021-07-12 | Signal Pharmaceuticals, Llc | Pakeistieji aminopurino junginiai, jų kompozicijos ir gydymo būdai jais |
| EP3233808B1 (en) | 2014-12-16 | 2021-07-14 | Signal Pharmaceuticals, LLC | Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin |
| CA2975260C (en) | 2015-01-29 | 2024-05-21 | Signal Pharmaceuticals Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| CN107635992B (zh) | 2015-03-18 | 2020-05-22 | 百时美施贵宝公司 | 用作tnf抑制剂的三环杂环化合物 |
| EA201792054A1 (ru) | 2015-03-18 | 2018-01-31 | Бристол-Майерс Сквибб Компани | Гетероциклические соединения, применимые в качестве ингибиторов tnf |
| CA2980159A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| MX385379B (es) | 2015-07-24 | 2025-03-18 | Celgene Corp | Metodos de sintesis de clorhidrato de (1r,2r,5r)-5-amino-2-metilciclohexanol e intermedios utiles en este. |
| MX2018001173A (es) | 2015-08-03 | 2018-04-24 | Squibb Bristol Myers Co | Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa. |
| CN109069512B (zh) * | 2016-04-01 | 2022-06-14 | 西格诺药品有限公司 | 取代的氨基嘌呤化合物、其组合物以及相关治疗方法 |
| PT3436019T (pt) * | 2016-04-01 | 2021-11-04 | Signal Pharm Llc | (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos |
| CN109476696B (zh) * | 2016-06-02 | 2022-06-10 | 细胞基因公司 | 动物及人抗锥虫和抗利什曼原虫剂 |
| ES2926149T3 (es) * | 2016-06-02 | 2022-10-24 | Celgene Corp | Agentes antipalúdicos animales y humanos |
| BR112020006599B1 (pt) * | 2017-10-04 | 2024-02-20 | Celgene Corporation | Cápsulas compreendendo cis-4-[2-{[(3s,4r)-3-fluoro-oxan-4-il]amino}-8-(2,4,6-tricl oroanilino)-9h-purin-9-il]-1-metilciclohexano-1-carb oxamida |
| US10590136B2 (en) * | 2017-10-04 | 2020-03-17 | Celgene Corporation | Processes for the preparation of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide |
| WO2022002118A1 (zh) * | 2020-07-01 | 2022-01-06 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| CN114478326B (zh) * | 2022-01-21 | 2023-10-03 | 安徽宁亿泰科技有限公司 | 一种苯嘧磺草胺关键中间体的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| FI109088B (fi) | 1997-09-19 | 2002-05-31 | Leiras Oy | Tabletti ja menetelmä sen valmistamiseksi |
| CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| US7672705B2 (en) * | 2004-07-19 | 2010-03-02 | Resonant Medical, Inc. | Weighted surface-to-surface mapping |
| US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7723340B2 (en) * | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7759342B2 (en) | 2005-01-13 | 2010-07-20 | Signal Pharmaceuticals, Llc | Methods of treatment and prevention using haloaryl substituted aminopurines |
| CN101360725B (zh) | 2005-11-18 | 2011-09-21 | 阿斯利康公司 | 固体制剂 |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
| KR20150028857A (ko) | 2006-10-27 | 2015-03-16 | 시그날 파마소티칼 엘엘씨 | 4-[9-(테트라하이드로-퓨란-3-일)-8-(2,4,6-트리플루오로-페닐아미노)-9ｈ-퓨린-2-일아미노]-사이클로헥산-1-올을포함하는 고체 형태들, 이들의 조성물들 및 이들의 용도 |
| US8491930B2 (en) | 2008-04-23 | 2013-07-23 | Farmasierra Manufacturing, S.L. | Pharmaceutical formulation containing ibuprofen and codeine |
| WO2011071491A1 (en) | 2009-12-09 | 2011-06-16 | Signal Pharmaceuticals, Llc | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| US8680076B2 (en) * | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
| US8603527B2 (en) | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
| WO2014172616A2 (en) | 2013-04-18 | 2014-10-23 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| LT3204386T (lt) | 2014-10-06 | 2021-07-12 | Signal Pharmaceuticals, Llc | Pakeistieji aminopurino junginiai, jų kompozicijos ir gydymo būdai jais |
| PT3436019T (pt) | 2016-04-01 | 2021-11-04 | Signal Pharm Llc | (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos |
-
2015
- 2015-10-05 LT LTEP15848476.6T patent/LT3204386T/lt unknown
- 2015-10-05 ES ES15848476T patent/ES2871142T3/es active Active
- 2015-10-05 CN CN202110381676.XA patent/CN113248506A/zh active Pending
- 2015-10-05 AU AU2015328414A patent/AU2015328414B2/en active Active
- 2015-10-05 JP JP2017538172A patent/JP6884701B2/ja active Active
- 2015-10-05 KR KR1020177010551A patent/KR102504849B1/ko active Active
- 2015-10-05 SG SG10202009598VA patent/SG10202009598VA/en unknown
- 2015-10-05 DK DK15848476.6T patent/DK3204386T3/da active
- 2015-10-05 PL PL15848476T patent/PL3204386T3/pl unknown
- 2015-10-05 MX MX2017004600A patent/MX388321B/es unknown
- 2015-10-05 HU HUE15848476A patent/HUE054694T2/hu unknown
- 2015-10-05 AR ARP150103202A patent/AR102171A1/es not_active Application Discontinuation
- 2015-10-05 TW TW104132732A patent/TW201629063A/zh unknown
- 2015-10-05 HR HRP20210656TT patent/HRP20210656T1/hr unknown
- 2015-10-05 EA EA201790779A patent/EA201790779A1/ru unknown
- 2015-10-05 SG SG11201702759XA patent/SG11201702759XA/en unknown
- 2015-10-05 WO PCT/US2015/053941 patent/WO2016057370A1/en not_active Ceased
- 2015-10-05 CN CN201580065272.2A patent/CN107001372B/zh active Active
- 2015-10-05 SI SI201531584T patent/SI3204386T1/sl unknown
- 2015-10-05 SM SM20210302T patent/SMT202100302T1/it unknown
- 2015-10-05 KR KR1020237006598A patent/KR20230035424A/ko not_active Withdrawn
- 2015-10-05 CA CA2963639A patent/CA2963639C/en active Active
- 2015-10-05 ES ES20214685T patent/ES2980464T3/es active Active
- 2015-10-05 PT PT158484766T patent/PT3204386T/pt unknown
- 2015-10-05 EP EP15848476.6A patent/EP3204386B1/en active Active
- 2015-10-05 US US14/874,513 patent/US9512124B2/en active Active
- 2015-10-05 EP EP20214685.8A patent/EP3822274B1/en active Active
- 2015-10-05 RS RS20210632A patent/RS61884B1/sr unknown
-
2016
- 2016-10-27 US US15/335,619 patent/US9737541B2/en active Active
-
2017
- 2017-04-04 IL IL251566A patent/IL251566B/en active IP Right Grant
- 2017-04-04 CL CL2017000820A patent/CL2017000820A1/es unknown
- 2017-04-06 MX MX2021014531A patent/MX2021014531A/es unknown
- 2017-04-20 CO CONC2017/0003838A patent/CO2017003838A2/es unknown
- 2017-04-27 EC ECIEPI201726210A patent/ECSP17026210A/es unknown
- 2017-07-05 US US15/641,383 patent/US10149849B2/en active Active
-
2018
- 2018-10-24 US US16/169,414 patent/US10398700B2/en active Active
-
2019
- 2019-07-17 US US16/514,749 patent/US10646493B2/en active Active
- 2019-10-02 JP JP2019182133A patent/JP6987823B2/ja active Active
-
2020
- 2020-02-28 AU AU2020201486A patent/AU2020201486B2/en active Active
- 2020-04-13 US US16/846,503 patent/US10940152B2/en active Active
- 2020-09-01 IL IL277069A patent/IL277069B/en unknown
-
2021
- 2021-01-12 US US17/147,127 patent/US11590139B2/en active Active
- 2021-05-24 CY CY20211100444T patent/CY1124173T1/el unknown
- 2021-12-01 JP JP2021195105A patent/JP7196270B2/ja active Active
-
2022
- 2022-12-14 JP JP2022199122A patent/JP2023027269A/ja active Pending
-
2023
- 2023-01-11 US US18/095,670 patent/US20230158035A1/en not_active Abandoned
- 2023-03-09 AR ARP230100589A patent/AR128748A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277069B (en) | Modified aminopurine compounds, their compositions and methods of treatment with them | |
| IL262007A (en) | Modified aminopurine compounds, their compositions and methods of treatment using them | |
| IL266560A (en) | Endophytes, related preparations and methods of using them | |
| CA3244408A1 (en) | Therapeutic compositions, combinations, and methods of use | |
| IL246252A0 (en) | Diaminopyrimidyl derivative compounds, their compositions and methods of treatment | |
| GB201701673D0 (en) | Methods of well treatment | |
| IL259246A (en) | Preparations containing pharmaceutical substances and methods of using them | |
| HUE056172T2 (hu) | Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra | |
| EP3207048A4 (en) | Compositions and methods of treating muscular dystrophy | |
| ZA201707303B (en) | Compositions and methods for the treatment of immunodeficiency | |
| PT3102555T (pt) | Composições de compostos e seus usos | |
| ZA201706257B (en) | Treatment of wood | |
| SG11201609254YA (en) | Therapeutic placental compositions, methods of making and methods of use | |
| LT3200815T (lt) | Būdai ir kompozicijos, skirti vėžio gydymui | |
| EP3139928A4 (en) | Anordrin compositions and methods for treating diseases | |
| PL2998311T3 (pl) | Mieszanina alkiloglikozydów, ich wytwarzanie i zastosowanie | |
| GB201416832D0 (en) | Methods of treatment | |
| EP3169405A4 (en) | Methods, compounds, and compositions for the treatment of musculoskeletal diseases | |
| GB201511799D0 (en) | Composition and methods of treatment | |
| IL251736B (en) | Methods and compositions for the treatment of radiation-related disorders | |
| IL252707B (en) | Compositions and methods for treating diseases | |
| ZA201608775B (en) | Hair treatment composition | |
| IL247645A0 (en) | Preparations of seleno-organic compounds and methods of using them | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201418272D0 (en) | Composition & methods of treatment |